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 BACKGROUND 
 Neonatal alloimmune thrombocytopenia (NAIT) occurs 
when fetal platelets contain an antigen that the mother 
lacks. The fetomaternal incompatibility for a platelet anti-
gen is due to the passage of antigen-positive fetal platelets 
into the circulation of an antigen-negative mother, causing 
maternal immunisation with production of immunoglobu-
lin G alloantibodies directed against the ‘foreign’ antigen. 
These alloantibodies cross the placenta bidding to foetal 
platelets and causing its destruction, resulting in severe 
foetal and neonatal thrombocytopenia. 1  2 
 Human platelet antigens (HPA) have different forms and 
its frequency varies with ethnicity. HPA-1a antigen is the 
commonest among caucasians, while the homozygous 
antigen for HPA-1b represents only 2.9%. 1  2 
 The incidence of NAIT is estimated to be 1/1000–5000 
births. It often develops in the ﬁ rst pregnancy of an 
unknown at-risk couple. Most NAIT newborn infants appear 
healthy and have an unexpected severe thrombocytopenia 
(<50×10 9 /l). Still, signs consistent with moderate to severe 
thrombocytopenia, including petechiae, bruising and bleed-
ing, can be present. Although skin bleeding may occur in 
almost half of the cases, intracranial haemorrhage is the most 
serious complication, present in about 8–22% of affected 
newborns, occurring in utero in 50–80% of cases. 1 – 4 
 Diagnosis of the ﬁ rst affected child include demonstra-
tion of thrombocytopenia in the newborn, maternal and 
paternal platelet antigen testing (phenotyping), antiplate-
let alloantibody testing in the mother’s serum and, when 
available, molecular study (genotying) of maternal, pater-
nal and child platelet antigens. 1 – 3 
 NAIT treatment must be instituted promptly. Compatible 
HPA platelets or washed maternal platelets are preferred 
as they will not be destroyed by maternal alloantibodies. 
Adequate platelet counts should be assured in the ﬁ rst 
3–4 days lowering the risk of intracranial haemorrhage. 
Intravenous immunoglobulin (IVIG) and methylpred-
nisolone are used as adjunctive therapy. 1  4 
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 Summary 
 Neonatal alloimmune thrombocytopenia is a rare (1/1000–5000 births) life-threatening disorder, caused by fetomaternal incompatibility 
for a fetal human platelet alloantigen inherited from the father, with production of maternal alloantibodies against fetal platelets, leading to 
severe thrombocytopenia and potential bleeding. Intracranial haemorrhage is the most feared complication. This report presents the case of 
a term newborn infant, born from caesarean section after a normal pregnancy, presenting signs of skin bleeding with different ages. Obstetric 
history included a previous spontaneous abortion after amniocentesis. Severe thrombocytopenia (4×10 9 /l platelets) was found and brain 
ultrasound showed multiple intracranial haemorrhages. Human platelet antigen (HPA) phenotyping showed maternal negative HPA-1a and 
paternal positive HPA-1a platelets. Strongly positive anti-HPA-1a and weakly positive anti-human leukocyte antigen class I alloantibodies were 
found in the mother. Multiple platelet transfusions, intravenous immunoglobulin and corticosteroid were given but favourable response was 
accomplished only after a compatible platelet transfusion. Brain MRI showed multiple subacute and chronic haemorrhages. 
 Figure 1  Clinical presentation: generalised bruising, suffusions and petechias. 
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 This case remembers the complexity of this disease, 
the importance of its rapid recognition and prompt 
management. 
 CASE PRESENTATION 
 The authors present the case of a newborn term female, 
ﬁ rst birth from a second pregnancy of healthy non-con-
sanguineous parents, presenting generalised bruising, suf-
fusions and petechias in different stages of development 
at birth. 
 Family medical history was normal. Obstetric maternal 
antecedents included a spontaneous abortion 1 year ear-
lier, soon after an amniocentesis, performed at 16 weeks 
of pregnancy, due to mother’s age (38 years old). The pre-
vious fetus had a normal female karyotype (46, XX) and 
phenotype on necropsy, also showing signs of intrauterine 
growth restriction and acute retroplacental haematoma. 
 The current pregnancy was uneventful. A female karyo-
type (46, XX) was obtained. Serological maternal investi-
gation was irrelevant (negative hepatitis B virus, hepatitis 
C virus, HIV and venereal disease research laboratory; 
immune to toxoplasma, rubella and cytomegalovirus) 
and routine fetal ultrasounds were normal. There was no 
maternal history of haemorrhage nor thrombocytopenia 
(>230×10 9 /l); mother’s blood group was A Rh D posi-
tive. She was born from caesarean section at 40 weeks 
 Figure 2  Transfontanelar ultrasound with hyperechogenic intracranial lesions (arrows) suggesting haemorrhage. 
 Figure 3  Treatment and platelet count response. TP-Random donor platelet transfusion; TPΘ-Platelet transfusion from a negative HPA-1a 
donor; IVIG-Intravenous immunoglobulin; MPDN-methylprednisolone. 
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gestation, due to fetopelvic incompatibility and abnormal 
cardiotocographic record, needing reanimation with bag-
mask ventilation with subsequent recovery (Apgar scores: 
4/8/9). Generalised bruising, suffusions and petechias 
in different stages of development were noted ( ﬁ gure 1 ). 
Hepatosplenomegaly was absent. Weight was adequate 
for gestational age (3330 g). 
 INVESTIGATIONS 
 Cord blood was obtained showing a severe isolated 
thrombocytopenia of 16×10 9 /l platelets. Peripheral blood 
conﬁ rmed the thrombocytopenia (lowest value 4×10 9 /l) 
and excluded a possible infectious cause (negative 
C-reactive protein and blood culture). Because NAIT was 
suspected, newborn cranial ultrasound and parental blood 
testing were performed. Cranial ultrasound ( ﬁ gure 2 ) in 
the ﬁ rst 2 h of life showed a right parieto-occipital hyper-
echoic and homolateral peri-sylvian lesions. Platelet HPA 
phenotyping in maternal and paternal blood showed 
negative HPA-1a and positive HPA-1a platelets, respec-
tively; the mother had strongly positive anti-HPA-1a 
and weakly positive anti-HLA class I alloantibodies; the 
mother’s serum and father’s platelet crossmatch proved 
to be incompatible. 
 Figure 4  Brain MRI. Axial T1WI (A) and T2WI (B): right parietal haemorrhage with blood in early and late subacute stage. Axial T2 
gradient echo (C) and sagittal T1WI (D): there are signs of chronic bleeding, with haemosiderin deposits (C) and marked atrophy (D) of the 
cerebellar hemispheres and vermis. 
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 TREATMENT 
 Medical treatment was started in the ﬁ rst hours of life 
( ﬁ gure 3 ). Due to the unavailability of compatible plate-
lets (negative HPA-1a), two platelet transfusions (20 ml/
kg/dose) from random donors were administered in day 
1 with count normalisation. IVIG (1 g/kg/day for 2 days) 
and intravenous methylprednisolone (3 mg/kg/day for 5 
days) were administered as adjunctive therapies. Despite 
this management and over the next 3 days, platelet count 
decreased (28×10 9 /l platelets) leading to a third compat-
ible platelet transfusion (negative HPA-1a donor) and IVIG 
administration. 
 OUTCOME AND FOLLOW-UP 
 Platelet count reached a normal plateau (>198×10 9 /l plate-
lets), signs of skin bleeding improved and cranial ultra-
sound was resemblant, at 5 days of life. Brain MRI on day 
8 ( ﬁ gure 4 ) showed multiple subacute cerebral haemor-
rhages (1–4 weeks of development) in the right parietal 
lobe and in the posterior fossa, signs of chronic bleeding 
(haemosiderin deposits) in the occipital lobes and cer-
ebellar hemispheres and vermis, these last also presenting 
marked atrophy. 
 At day 11 of life, she was discharged home without 
clinical manifestations of neither bleeding nor focal deﬁ cits 
on neurological examination. Platelet count was normal 
(222×10 9 /l platelets). 
 At 3 weeks life in the paediatric haematology consulta-
tion, molecular study was performed showing homozygous 
platelet alloantigen genotypes 1b/1b in the mother and 
1a/1a in the father; the newborn was proved to be hetero-
zygous HPA-1a/1b. Genetic counselling was offered. 
 DISCUSSION 
 Any newborn infant with platelet count below 100×10 9 /l 
should be considered abnormal and promptly studied for 
an underlying cause. 3 NAIT is a rare severe condition. It 
must be suspected if clinical manifestations such as skin 
or gastrointestinal bleeding or intracranial haemorrhage 
on ultrasound and severe thrombocytopenia are present, 
in the absence of maternal thrombocytopenia. Because 
maternal screening is rarely performed, couples usually 
do not know they are at risk until they have delivered an 
affected child. 1  3  5 The mother is asymptomatic, yet she or 
a sister may have a history of earlier affected pregnancies. 4 
In the previous case there was a history of spontaneous 
abortion 1 year earlier, after an amniocentesis at 16 weeks 
of pregnancy. This episode could have been related to foe-
tal alloimmune thrombocytopenia. An explanation is that 
fetal platelet antigens are expressed since week 16 of ges-
tation entering the maternal circulation. Antiplatelet anti-
bodies can endure in maternal circulation for many years 
and additional exposure in subsequent pregnancies can be 
a further stimulus. Severity of NAIT tends to worsen with 
subsequent pregnancies, leading to an increased risk for 
intracranial haemorrhage. 1  4 In our case, brain MRI showed 
that although undetected in fetal ultrasound, intracranial 
haemorrhage occurred in utero. 
 Infants with NAIT and intracranial haemorrhage have 
the poorest outcome. Mortality can range from 15% to 
30% of these cases. 4  6 Non-fatal cases usually are asso-
ciated with neurologic sequelae including cerebral palsy, 
mental retardation, cortical blindness and seizures. When 
intracranial haemorrhage occurs in utero before week 20, 
abnormalities like porencephalic cysts, hydrocephaly, neu-
ronal migrational disorders and superﬁ cial siderosis are 
often present. 4 Due to the severe central nervous system 
abnormalities affecting the motor and coordination centers 
in our case, some compromise in the neurodevelopment is 
expected. 
 The treatment of severe NAIT with platelet transfusion 
takes into account the threshold of the platelet count. Term 
newborns with less than 30×10 9 /l platelets and preterm 
infants with less than 50×10 9 /l platelets should be transfused, 
especially if bleeding is present. Intravenous γ-globulin (1 g/
kg/day for 1–4 days) is effective in 75% of cases but takes 
longer than does a platelet transfusion to achieve a safe 
platelet count. Intravenous methylprednisolone (1 mg/kg, q 
8 h, 1–3 days) lacks on efﬁ cacy studies. 1  4 
 Because of the high risk of recurrence of NAIT, all women 
with a history of NAIT must be counselled. Sisters of HPA-
1a–negative women should also be tested. 2  4 Attending the 
father’s homozygous genotype in the previous case, this 
couple will always produce HPA-1a/1b infants, who will 
be affected by this condition if antenatal management is 
not fulﬁ lled. Although the severity of NAIT is often dif-
ﬁ cult to predict, it is known that it tends to worsen with 
subsequent pregnancies. 4 Bussel  et al. showed that a history 
of intracranial haemorrhage in a previously affected sibling 
is the only signiﬁ cant predictor of severity. 7 For this reason, 
if this couple decides to proceed with a future pregnancy 
they must be closely monitored and treatment should be 
offered. In a couple with a previous affected infant, ade-
quate therapy is maternal weekly IVIG from 20 weeks of 
gestation or earlier (12 weeks) if intracranial haemorrhage 
is present. Increase of the IVIG dose or daily prednisone 
may be used when a more intense prevention strategy is 
needed. Maternal anti-HPA-1a antibodies should be moni-
tored. Antenatal management should avoid invasive pro-
cedures such as in utero platelet transfusions because of 
the high risk of fetal loss (5.5% per affected pregnancy). 
Elective caesarean delivery should be performed, minimis-
ing the haemorrhagic risks. 2  4  8 
 Learning points 
 ▶  Suspect of NAIT in a well newborn who presents with 
bruising, petechial rash and/or suffusions and who is 
found to have isolated severe thrombocytopenia. 
 Careful inquire about maternal personal and familial  ▶
history and obstetric follow-up, including maternal 
platelet count. 
 Treatment should include adequate platelet transfusion  ▶
(HPA-1a/ HPA-5b negative platelets) and IVIG as earlier 
as possible to prevent bleeding complications. If 
adequate platelet transfusion is not available, random 
donor platelets should be used. 
 Intracranial haemorrhage is the most serious  ▶
complication with catastrophic neurologic sequelae. 
 Genetic counselling should be offered to couples of  ▶
affected children who want to have future pregnancies. 
Antenatal management is crucial in prevention of a 
poor outcome. 
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